The biological role of the CXCL12/CXCR4 axis in esophageal squamous cell carcinoma.
The biological role of the CXCL12/CXCR4 axis in esophageal squamous cell carcinoma.
复制标题
CXCL12/CXCR4轴在食管鳞状细胞癌中的生物学作用
DOI：
10.20892/j.issn.2095-3941.2020.0140
复制
发表时间：
2021-03-12
影响因子：
5.5
通讯作者：
Yu Z
中科院分区：
文献类型：
--
作者：
Wu X;Zhang H;Sui Z;Wang Y;Yu Z
食管癌是全球第八大常见恶性肿瘤，也是第六大癌症相关死亡原因。食管鳞状细胞癌（ESCC）是食管癌的主要组织学类型，占所有癌症病例的90%。尽管手术、化疗和放疗取得了进展，但食管癌的死亡率仍然很高，即使在发达国家，总体5年生存率也不足20%。 C-X-C基序趋化因子配体12（CXCL12）是CXC趋化因子亚组的成员，广泛表达于多种组织和细胞中。 CXCL12 通过与其特异性受体 C-X-C 基序趋化因子受体 4 型 (CXCR4) 结合，参与许多生理和病理过程的调节，从而引起胚胎发育、免疫反应和血管生成。此外，越来越多的证据表明CXCL12/CXCR4轴在肿瘤细胞的生物学过程中发挥着重要作用。研究表明CXCL12及其受体CXCR4在ESCC中高表达。这种异常表达会导致肿瘤增殖、淋巴结和远处转移以及预后恶化。目前，已经开发出针对CXCL12或CXCR4的拮抗剂和显像剂来干扰肿瘤的恶性过程并监测肿瘤的转移。本文综述了CXCL12/CXCR4的结构、功能、调控机制及其在食管鳞癌恶性肿瘤中的作用。还总结了目前针对CXCL12/CXCR4的临床前研究结果，为ESCC的临床诊断和治疗提供参考。
Esophageal cancer is the eighth most common malignant tumor and the sixth leading cause of cancer-related death worldwide. Esophageal squamous cell carcinoma (ESCC) is the main histological type of esophageal cancer, and accounts for 90% of all cancer cases. Despite the progress made in surgery, chemotherapy, and radiotherapy, the mortality rate from esophageal cancer remains high, and the overall 5-year survival rate is less than 20%, even in developed countries. The C-X-C motif chemokine ligand 12 (CXCL12) is a member of the CXC chemokine subgroup, which is widely expressed in a variety of tissues and cells. CXCL12 participates in the regulation of many physiological and pathological processes by binding to its specific receptor, C-X-C motif chemokine receptor type 4 (CXCR4), where it causes embryonic development, immune response, and angiogenesis. In addition, increasing evidence indicates that the CXCL12/CXCR4 axis plays an important role in the biological processes of tumor cells. Studies have shown that CXCL12 and its receptor, CXCR4, are highly expressed in ESCC. This abnormal expression contributes to tumor proliferation, lymph node and distant metastases, and worsening prognosis. At present, antagonists and imaging agents against CXCL12 or CXCR4 have been developed to interfere with the malignant process and monitor metastasis of tumors. This article summarizes the structure, function, and regulatory mechanism of CXCL12/CXCR4 and its role in the malignancy of ESCC. Current results from preclinical research targeting CXCL12/CXCR4 are also summarized to provide a reference for the clinical diagnosis and treatment of ESCC.
登录
查看更多内容
影响因子：
29.4
作者：
Garg B;Giri B;Modi S;Sethi V;Castro I;Umland O;Ban Y;Lavania S;Dawra R;Banerjee S;Vickers S;Merchant NB;Chen SX;Gilboa E;Ramakrishnan S;Saluja A;Dudeja V
通讯作者：
Dudeja V
影响因子：
7.7
作者：
Codipilly DC;Qin Y;Dawsey SM;Kisiel J;Topazian M;Ahlquist D;Iyer PG
通讯作者：
Iyer PG
影响因子：
120.1
作者：
De Clercq, E
通讯作者：
De Clercq, E
影响因子：
16.6
作者：
Givel AM;Kieffer Y;Scholer-Dahirel A;Sirven P;Cardon M;Pelon F;Magagna I;Gentric G;Costa A;Bonneau C;Mieulet V;Vincent-Salomon A;Mechta-Grigoriou F
通讯作者：
Mechta-Grigoriou F
影响因子：
8
作者：
Ahirwar DK;Nasser MW;Ouseph MM;Elbaz M;Cuitiño MC;Kladney RD;Varikuti S;Kaul K;Satoskar AR;Ramaswamy B;Zhang X;Ostrowski MC;Leone G;Ganju RK
通讯作者：
Ganju RK